These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

741 related items for PubMed ID: 32758491

  • 1. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H, Glasgow A, Bomeisl P, Gilmore H, Harbhajanka A.
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [Abstract] [Full Text] [Related]

  • 2. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C, You S, Mendoza PM, Aneja R, Sahin AA, Li X.
    Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA, Alhassoon S, Sughayer HM.
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [Abstract] [Full Text] [Related]

  • 4. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
    Park MM, Ebel JJ, Zhao W, Zynger DL.
    Breast J; 2014 Aug; 20(1):37-45. PubMed ID: 24261318
    [Abstract] [Full Text] [Related]

  • 5. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M, Rosman M, Mylander C, Tafra L.
    Breast J; 2013 Aug; 19(4):357-64. PubMed ID: 23701403
    [Abstract] [Full Text] [Related]

  • 6. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K, Wang Y, Marketkar S, Kalife ET, Steinhoff MM.
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [Abstract] [Full Text] [Related]

  • 7. Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.
    Kraus JA, Dabbs DJ, Beriwal S, Bhargava R.
    Mod Pathol; 2012 Jun; 25(6):869-76. PubMed ID: 22301704
    [Abstract] [Full Text] [Related]

  • 8. In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.
    Tyburski H, Karakas C, Finkelman BS, Turner BM, Zhang H, Hicks DG.
    Lab Invest; 2024 Mar; 104(3):100309. PubMed ID: 38135156
    [Abstract] [Full Text] [Related]

  • 9. Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.
    Loggie J, Barnes PJ, Carter MD, Rayson D, Bethune GC.
    Breast; 2024 Jun; 75():103715. PubMed ID: 38520994
    [Abstract] [Full Text] [Related]

  • 10. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A, Sechrist H, Bomeisl P, Gilmore H, Harbhajanka A.
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [Abstract] [Full Text] [Related]

  • 11. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
    Chaudhary LN, Jawa Z, Szabo A, Visotcky A, Chitambar CR.
    Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):48-54. PubMed ID: 26808222
    [Abstract] [Full Text] [Related]

  • 12. Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
    van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, Menke-van der Houven van Oordt CW, Verheul HM, van Herpen CML, Jager A, Oosting SF, de Vries EGE, Schröder CP.
    Am J Surg Pathol; 2019 Oct; 43(10):1355-1360. PubMed ID: 31283631
    [Abstract] [Full Text] [Related]

  • 13. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H, Webber M, Wall D, Scarrott C, Newell J, Callagy G.
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [Abstract] [Full Text] [Related]

  • 14. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J, Piscuoglio S, Aggarwal G, Magda J, Friedlander MA, Murray M, Akram M, Reis-Filho JS, Weigelt B, Edelweiss M.
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [Abstract] [Full Text] [Related]

  • 15. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
    Karsten M, Stempel M, Radosa J, Patil S, King TA.
    Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
    [Abstract] [Full Text] [Related]

  • 16. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J, Kim M, Fineberg S.
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [Abstract] [Full Text] [Related]

  • 17. HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX.
    Tozbikian GH, Zynger DL.
    Breast J; 2018 Jul; 24(4):535-540. PubMed ID: 29498449
    [Abstract] [Full Text] [Related]

  • 18. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
    Bauer K, Parise C, Caggiano V.
    BMC Cancer; 2010 May 21; 10():228. PubMed ID: 20492696
    [Abstract] [Full Text] [Related]

  • 19. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA, Joshi AR, Khandeparkar SGS, Kulkarni MM, Gogate BP, Kakade AR, Sahu PD, Khillare CD.
    Indian J Cancer; 2020 May 21; 57(2):190-197. PubMed ID: 32445323
    [Abstract] [Full Text] [Related]

  • 20. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF, Li JL, Luo CP, Wei CH, Lu YK, Liu HZ, Wei WE, Zhang LT.
    Int J Clin Exp Pathol; 2014 May 21; 7(12):8740-7. PubMed ID: 25674240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.